UPDATE CONCERNING COVID-19 (NOVEL CORONAVIRUS)
Due to the COVID-19 situation, the 21st International Conference on Alzheimer’s Drug Discovery will be hosted online.
To access the live sessions of the conference, you must be registered.
If already registered, please click here to access the virtual hub.
This annual conference will showcase the innovative approaches of Alzheimer’s Drug Discovery Foundation’s (ADDF) funded scientists and their newest results. In addition to featuring ADDF’s portfolio, the program will also include guest presentations focusing on the latest research in the Alzheimer’s disease field.
The program features five sessions:
- Novel Approaches for Neuroinflammation
- Metabolic and Mitochondrial Approaches for Alzheimer’s Disease
- Emerging Areas in Drug Development for Neurodegeneration
- Neuroprotection, Synaptic Health and Neurotransmitters
- Novel Biomarkers in Alzheimer’s Disease
The registration for this conference will be free though a brief form available at the Registration page.
OBJECTIVES
- Highlight scientific progress on drug development and biomarker programs aimed at treating Alzheimer’s disease and related dementias.
- Increase opportunities for early career investigators and start-up companies to share information and resources.
- Foster interdisciplinary and public-private partnerships and alliances.
SHORT PRESENTATION DEADLINE
The deadline to submit an entry for the Virtual Poster or the Start-up Forum presentations is August 21, 2020.
CONFERENCE HIGHLIGHTS

22 Speakers

Virtual Poster Presentations

Start-up Forum

Virtual Q&A

Ample sponsorship opportunities

Complimentary Registration
FOCUS
The purpose for this annual ADDF conference is to accelerate the development of innovative treatments for Alzheimer’s disease, related dementias and cognitive aging.
Attendees will see the diverse cutting-edge approaches ADDF scientists are undertaking and have opportunities for networking and partnership discussions with academic, industry, and foundation thought leaders.
AUDIENCE
The 2019 edition of this conference attracted close to 130 attendees from around the world. Attendees included:
- Academic and industry scientists engaged in drug discovery and biomarker research for neurodegenerative diseases and CNS
- Business development and licensing professionals
- Alliance management professionals
- Venture capitalists and other investors
- Graduate students, PhD candidates and post-doctoral fellows.
SPEAKERS AND CHAIRS






Darren Baker
Mayo Clinic
CJ Barnum
INmune Bio
Nicole Bjorklund
ADDF
Ronald Crystal
Weill Cornell MC
Paul Edison
ICL
Howard Fillit
ADDF






Hüseyin Firat
Amoneta
Lauren Friedman
ADDF
Douglas Galasko
UC San Diego
Gary Gibson
Burke Neuro. Inst
Mark Gurney
Tetra Therapeutics
Lampros Kourtis
Circadic






Chunlei Liu
UC Berkeley
Nick McKeehan
ADDF
Ralph Nixon
NS Kline Inst.
Meriel Owen
ADDF
Ana Pereira
ISMMS
Dianne Perez
CCF






Martin Pomper
Johns Hopkins U.
Sharon Rosenzweig-Lipson
AgeneBio
Kira Sheinerman
DiamiR Biosciences
Jeffrey Stavenhagen
TheriniBio
Sidney Strickland
The Rockefeller Univ.
Alessio Travaglia
ADDF



Linda Van Eldik
Univ. of Kentucky
Henrik Zetterberg
Univ. of Gothenburg
Berislav Zlokovic
USC
Join us today!
submitting an application for a virtual poster or start-up presentation or simply, spread the word about it!